POLICY STATEMENT:

I. Recombinant Platelet-Derived Growth Factors: Becaplermin gel, Regranex®
   A. Based upon our criteria and assessment of peer-reviewed literature, recombinant human platelet-derived growth factor (Becaplermin gel) for topical administration has been medically proven to be effective and therefore medically appropriate when used as an adjunct to standard wound management for *neuropathic diabetic ulcers* extending into the subcutaneous tissue. Appropriate candidates should meet ALL of the following criteria:
   1. Adequate tissue oxygenation, as measured by:
      a. a transcutaneous partial pressure of oxygen of 30 mm Hg or greater on the foot dorsum or at the margin of the ulcer, or
      b. an ankle-brachial blood pressure index (ABI) greater than 0.70 or ankle systolic pressure greater than 70 mm Hg
   2. Full-thickness ulcer (ie, stage III or IV), extending through dermis into subcutaneous tissues
   3. Participation in a wound management program, which includes sharp debridement, pressure relief (ie, non-weight bearing), and infection control.
   B. Based upon our criteria and lack of peer-reviewed literature, Becaplermin gel has not been medically proven to be effective and is considered investigational for all of the following indications:
      1. Ischemic diabetic ulcers
      2. Venous stasis ulcers
      3. Pressure ulcers
      4. Ulcers not extending through the dermis into the subcutaneous tissue
      5. Surgical wounds
      6. Ulcerated perineal hemangiomas of infancy

II. Autologous Platelet-Derived Preparations: Basic Fibroblast Growth Factor (BFGF), Epidermal Growth Factor (EGF), Placental Angiogenic Growth Factors (PGF’s), and Platelet-Rich Plasma (PRP)
   Based upon our criteria and lack of peer-reviewed literature, autologous platelet-derived preparations have not been medically proven to be effective and are considered investigational in the treatment of:
   A. Chronic non-healing wounds
   B. Surgical wounds
   C. All other conditions including, but not limited to: arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis, and tendinopathy.

This policy does not address fibrin sealants.
Refer to Corporate Medical Policy #7.01.35 regarding Bioengineered Tissue Products for Wound Treatment and Surgical Interventions.
Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.

POLICY GUIDELINES:

I. Patients are typically treated once daily for up to 20 weeks. Continuing Becaplermin treatment should be reconsidered if the ulcer is not reduced in size by 30% within 10 weeks of treatment or complete healing has not
Questions still remain about their efficacy. An increasingly popular application of cell types essential for wound healing. The growth promoting activities of derived growth factor (PDGF) are thought to be deficient in chronic wounds. Autologous platelet-derived growth factor preparations have been proposed as an adjuvant therapy for wound healing and to enhance healing following various types of surgery (e.g., oral and maxillofacial surgery, dental implants, non-union fractures). Platelet-rich plasma (PRP) preparations, which contain growth factors, have been proposed as a primary treatment of miscellaneous conditions, such as arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis and tendinopathy. The effectiveness of PDGF and PRP use, for these conditions, has not been demonstrated in the peer-reviewed literature.

RATIONALE:

Becaplermin (Regranex) gel has been approved by the FDA specifically for use in the treatment of chronic neuropathic diabetic ulcers of the lower extremities. Becaplermin gel, in conjunction with a good wound care program, has been found to improve health outcomes of patients with chronic neuropathic diabetic ulcers by producing complete wound healing and reducing the time to complete wound healing when compared to a good wound care program alone. In 2008, the manufacturer of Regranex gel, Ortho-McNeil Pharmaceutical, added a black box warning to the labeling stating an increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of Regranex gel in a post-marketing retrospective cohort study. Regranex gel should only be used when the benefits can be expected to outweigh the risks, and Regranex gel should be used with caution in patients with known malignancy. Available data are insufficient to permit positive conclusions regarding the use of Becaplermin gel for treatment of ulcers (e.g., ischemic diabetic ulcers, pressure ulcers, and venous ulcers), other than chronic neuropathic diabetic ulcers, or other non-healing wounds in the investigational setting. Evidence is insufficient regarding the use of platelet-derived growth factors as a treatment of chronic non-healing wounds, surgical wounds, and other conditions, including but not limited to, arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis, or tendinopathy.

A 2015 statement by the American Academy of Orthopedic Surgeons states “Biologic therapies are becoming increasingly popular in orthopedics due to their potential to regenerate tissue and enhance bone healing. However, questions still remain about their efficacy and indications for use.”
Published studies provide mixed results regarding the use of PRP; with some showing benefit of the treatment while others show no or little benefit. Proof of the efficacy of PRP has not been demonstrated in clinical studies and further well-designed, randomized, controlled studies are needed before conclusion can be made.

**CODES:**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.</td>
<td></td>
</tr>
<tr>
<td>CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.</td>
<td></td>
</tr>
<tr>
<td>Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.</td>
<td></td>
</tr>
<tr>
<td>CPT: 0232T (E/I) Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed</td>
<td></td>
</tr>
<tr>
<td>Copyright © 2017 American Medical Association, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>HCPCS: G0460 (E/I) Autologous platelet rich plasma for chronic wounds/ulcers including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment</td>
<td></td>
</tr>
<tr>
<td>P9020 (E/I) Platelet rich plasma, each unit</td>
<td></td>
</tr>
<tr>
<td>S0157 Becaplermin gel 0.01%, 0.5 gm</td>
<td></td>
</tr>
<tr>
<td>S9055 Procuren or other growth factor preparation to promote wound healing</td>
<td></td>
</tr>
<tr>
<td>NDC: 50484-0810-15 Becaplermin</td>
<td></td>
</tr>
<tr>
<td>ICD9: 707.1 Ulcer of lower limb, except pressure ulcer</td>
<td></td>
</tr>
<tr>
<td>250.8 Diabetes with other specified manifestations</td>
<td></td>
</tr>
<tr>
<td>ICD10: Medically Appropriate codes for when criteria is met under Policy Statement IA:</td>
<td></td>
</tr>
<tr>
<td>E08.621 Diabetes mellitus due to underlying condition with foot ulcer</td>
<td></td>
</tr>
<tr>
<td>E08.622 Diabetes mellitus due to underlying condition with other skin ulcer</td>
<td></td>
</tr>
<tr>
<td>E09.621 Drug or chemical induced diabetes mellitus with foot ulcer</td>
<td></td>
</tr>
<tr>
<td>E09.622 Drug or chemical induced diabetes mellitus with other skin ulcer</td>
<td></td>
</tr>
<tr>
<td>E10.621 Type 1 diabetes mellitus with foot ulcer</td>
<td></td>
</tr>
<tr>
<td>E10.622 Type 1 diabetes mellitus with other skin ulcer</td>
<td></td>
</tr>
<tr>
<td>E11.621 Type 2 diabetes mellitus with foot ulcer</td>
<td></td>
</tr>
<tr>
<td>E11.622 Type 2 diabetes mellitus with other skin ulcer</td>
<td></td>
</tr>
<tr>
<td>E13.621 Other specified diabetes mellitus with foot ulcer</td>
<td></td>
</tr>
<tr>
<td>E13.622 Other specified diabetes mellitus with other skin ulcer</td>
<td></td>
</tr>
<tr>
<td>ICD10: Investigational codes (See Policy Statement IB):</td>
<td></td>
</tr>
<tr>
<td>I70.231-I70.249 Atherosclerosis of native arteries of leg with ulceration (code range)</td>
<td></td>
</tr>
<tr>
<td>I70.331-I70.349 Atherosclerosis of unspecified type of bypass graft(s) of leg with ulceration (code range)</td>
<td></td>
</tr>
</tbody>
</table>

*Proprietary Information of Excellus Health Plan, Inc.*
I70.431-I70.449 Atherosclerosis of autologous vein bypass graft(s) of the leg with ulceration (code range)

I70.531-I70.549 Atherosclerosis of nonautologous biological bypass graft(s) of the leg with ulceration (code range)

I70.631-I70.649 Atherosclerosis of nonbiological bypass graft(s) of the leg with ulceration (code range)

I70.731-I70.749 Atherosclerosis of other type of bypass graft(s) of the leg with ulceration (code range)

L97.101-L97.929 Non-pressure chronic ulcer of lower extremity (code range)

L89.30-L89.95 Pressure ulcers (code range)

REFERENCES:


Proprietary Information of Excellus Health Plan, Inc.


SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS

POLICY NUMBER: 2.01.24
CATEGORY: Technology Assessment

EFFECTIVE DATE: 01/20/00
REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) for Blood-Derived Products for Chronic Non-Healing Wounds. Please refer to the following websites for Medicare Members:
http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=217&ncdver=5&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Entire+State&KeyWord=blood+derived+products&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAAABAAAAAAA%3d%3d


KEY WORDS:
Becaplermin, Growth factors, Regranex, Platelet derived growth factor, PDGF, Platelet-rich plasma.